A new wave of experimental cancer drugs that directly recruit the immune system’s powerful T cells could begin reaching patients next year, according to companies presenting new data at the annual meeting of the American Society of Clinical Oncology. In interviews with Reuters, Kite Pharma Inc
Chimeric Antigen Receptor T-cell therapy: targeted, specific, individualised. The pinnacle of immunotherapy for cancer, infection and autoimmunity.
An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated…
Novartis beats Juno Therapeutics to report encouraging proof-of-concept results of Chimeric Antigen Receptor in T-cells (CAR-T) immunotherapy in cancer.
Modified CAR-T cells can be used as in vivo…
“Controlling immune cells with light during the #cancer – immunity cycle: Zhou&co @TAMU discuss emerging tools in @TrendsinBiotech”
twitter.com|By Trends in Immunology